Amanta Healthcare Ltd Upgraded to Hold on Improved Technicals and Financial Performance

Technical Trend Shift Spurs Upgrade

The most significant catalyst behind the rating change is the upgrade in Amanta Healthcare’s technical grade from mildly bearish to mildly bullish. This shift is supported by several key technical indicators. On a weekly basis, the Bollinger Bands signal a bullish trend, while the On-Balance Volume (OBV) also shows mild bullishness on both weekly and monthly charts. The Dow Theory assessment is mildly bullish weekly, although it remains bearish monthly, indicating some caution among longer-term investors.

Despite the absence of clear signals from the Relative Strength Index (RSI) and Moving Average Convergence Divergence (MACD) on weekly and monthly timeframes, the overall technical momentum has improved. The stock’s daily price action has been positive, with the current price at ₹109.19, up 3.64% from the previous close of ₹105.35. The 52-week trading range remains wide, with a low of ₹93.25 and a high of ₹154.85, suggesting room for volatility but also potential upside.

Financial Trend: Strong Quarterly Performance

Amanta Healthcare’s financial trend has also contributed to the upgrade. The company reported robust results for the third quarter of fiscal year 2025-26, with net sales reaching a quarterly high of ₹74.49 crores. Profit After Tax (PAT) for the nine months ended December 2025 surged by 73.88% to ₹10.75 crores, signalling strong operational efficiency and profitability gains.

Operating profit to interest coverage ratio stands at a healthy 3.04 times, indicating improved ability to service debt obligations in the short term. Return on Capital Employed (ROCE) is at 14%, reflecting an attractive valuation metric, further supported by an enterprise value to capital employed ratio of 1.7. These figures underscore the company’s improving financial health despite its micro-cap status.

Quality Assessment: Mixed Long-Term Fundamentals

While the short-term financials and technicals have improved, Amanta Healthcare’s long-term fundamental strength remains weak. The company has experienced a negative compound annual growth rate (CAGR) of -2.00% in net sales over the past five years, signalling challenges in sustaining growth momentum. Additionally, the company’s debt servicing capacity is under pressure, with a high Debt to EBITDA ratio of 3.11 times, which raises concerns about long-term financial stability.

Promoters remain the majority shareholders, which often provides stability in governance and strategic direction. However, the micro-cap status and relatively modest market capitalisation mean the stock remains susceptible to volatility and liquidity constraints.

Valuation: Attractive but Cautious

From a valuation standpoint, Amanta Healthcare presents an attractive profile. The ROCE of 14% and an enterprise value to capital employed ratio of 1.7 suggest the stock is reasonably priced relative to its capital base and earnings potential. However, the stock’s 52-week high of ₹154.85 compared to the current price of ₹109.19 indicates a significant discount, possibly reflecting market scepticism about the company’s longer-term prospects.

Comparatively, the stock has outperformed the Sensex over recent short-term periods. For instance, it delivered an 11.42% return over the past week and 9.08% over the last month, while the Sensex declined by 2.60% and 8.62% respectively. Year-to-date, Amanta Healthcare’s return is marginally positive at 0.45%, contrasting with the Sensex’s negative 13.96% return. This relative outperformance highlights the stock’s resilience amid broader market weakness.

Technical Outlook: Mildly Bullish Momentum

The upgrade in technical grade is a key driver behind the rating change. The weekly Bollinger Bands indicate a bullish trend, supported by mildly bullish OBV readings on both weekly and monthly charts. The Dow Theory’s weekly mildly bullish stance further reinforces positive momentum. However, the monthly Dow Theory remains bearish, suggesting that investors should remain cautious about potential reversals or volatility in the medium term.

Overall, the technical indicators suggest a transition from a previously cautious stance to a more optimistic outlook, justifying the upgrade from Sell to Hold. The stock’s recent price appreciation of 3.64% in a single day reflects this renewed investor interest.

Summary and Investor Takeaway

Amanta Healthcare Ltd’s upgrade to a Hold rating reflects a balanced view of its current position. The company’s improved technical indicators and strong quarterly financial performance provide a foundation for cautious optimism. However, the weak long-term sales growth and elevated debt levels temper enthusiasm, suggesting that investors should monitor the company’s ability to sustain profitability and manage leverage.

Given the stock’s micro-cap status and volatility, it may appeal to investors with a higher risk tolerance who are looking for potential turnaround stories within the Pharmaceuticals & Biotechnology sector. The relative outperformance against the Sensex in recent months adds to its appeal as a tactical holding rather than a core portfolio stock at this stage.

Overall, the Hold rating signals that while the stock is no longer a sell, it does not yet warrant a Buy recommendation until further improvements in fundamentals and technicals are confirmed.

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today